RESCON–SUMMIT
EUROPE

Barcelona Hotel Renaissance
Barcelona, Spain

27 — 28 JUNE 2024
RESCON EUROPE 2024

Inhalation & RESpiratory Drug Delivery | CONnected Devices

DIAMOND SPONSORS

SILVER SPONSORS

EXHIBITORS

MEDIA PARTNERS

reddot winner 2023

Helping you bring inhaled medicines to market

See how our inhaled development **expertise,** formulation **science** and device **technology** can accelerate your programme

Visit **www.vectura.com** to find out more

VECTURA

RESCON Europe is a prestigious and highly anticipated event that builds on the success of its previous editions in New York. Dedicated to Inhalation & Respiratory Drug Delivery | Connected Devices, it brings together leading experts from the pharmaceutical, biotechnology industry, and academia.
The conference showcases cutting-edge innovations, emerging trends, and the latest advancements in respiratory drug delivery, aerosol science, device design, and digital applications.
It offers a valuable platform for knowledge exchange, networking, and shaping the future of inhalation and respiratory therapeutics.

Harro Höfliger

ALL YOU NEED

Technology and know-how

YOUR INHALATION PRODUCT IN FOCUS



We have many years of expertise in development and production equipment for drug delivery in inhalation and nasal applications. Our experts can support you in all aspects of the development and optimization of your inhalation product.

- Expertise in microdosing, sealing and assembly
- Turnkey solutions for inhaler industrialisation
- From clinical trials to commercial production
- Integration of dose verification and PAT

Looking forward to your visit at Rescon Summit, Barcelona 2024

EPM Group Executive Summary

WHO You Will Meet



80+
Attendees

20+
Speakers

RATIO

Bio/pharmaceutical manufacturing **65:35** Vendor/Solution Providers

Company Size of Attendees



- 1000+ employees
- 300-999 employees
- 50-299 employees
- less than 49 employees

Job Title of Attendees



- C-level
- SVP/VP
- Snr Director/Director
- Snr Manager/Manager

Attendee Company Annual Turnover



- 1 Billion
- $500-999Million
- $50-499 Million
- <50 Million

HOW You Will Benefit

x1000+

Relive the conference full Acess to documentation, footagesand videos.

x10+

Hours of Networking forge new professional contacts.

x20+

Case Studies Analisys

Companies Attending

FEEDBACK

94%

RATED EVENT AS

★★★★★

Quality of the speakers

Sharing of the best practices

Spectrum of industries

Intimate atmosphere

Short-quick presentations

98%

WOULD RECOMMEND THE EVENT TO COLLEAGUES

Learn
The Key Practical Points



- Understanding the role of X-Ray as a process analytical technology in the development of DPI blister formulations.
- Gaining insights into pre-clinical research methodologies and their significance in evaluating inhalation therapies.
- Exploring innovative approaches to mitigate N-Nitrosamine risks using advanced material science innovations in inhalation products.
- Navigating technical and regulatory challenges in the evolution of metered dose inhaler formulations towards low GWP propellants for climate and patient benefits.
- Analyzing the impact of Industry 4.0 inhalation devices on patient care, environmental sustainability, and advancements in medical technology.
- Leveraging partnerships with material suppliers to achieve sustainability goals in the development of medical devices for inhalation therapy.
- Staying abreast of evolving regulatory expectations for ensuring biological safety in breathing gas pathway devices.

- Examining the potential of inhaled chemotherapy as a novel modality to enhance immunotherapy response in lung cancer treatment.

- Developing effective drug delivery strategies for high doses and biologics to the lung through innovative techniques.

- Exploring emerging trends in respiratory device design and regulatory strategies to maintain a sustainable competitive advantage in the industry.

Meet
The Speakers

Ana Grenha

Associate Professor at University of Algarve

Badre Hammond

VP Global Commercial Operations & GM APAC at Aptar CSP Technologies

Felix Weiland

Head of Device Technology at Boehringer Ingelheim microParts GmbH

David Edwards

Associate Professor at Harvard University & Advisory Board at Johns Hopkins Medical School

Gunilla Petersson

Strategic Scientific Advisor at HCmed Innovations Co., Ltd.

Lina Burman

Senior Scientific Affairs Manager at Veranex

Loy Britto

Chief Executive Officer at Healthy Airways LLC

Nathalie Wauthoz

Associate Professor at Université libre de Bruxelles

Marco Franza

Director Sales and Business Development at Berry Global

Deepika Lakhani

Senior Vice President, Chief Regulatory & Quality Officer at PAVmed Inc.

Jacqueline van Druten

Clinical & Regulatory Affairs Director at CLIN-r+



Lucila Garcia-Contreras

Associate Professor at Oklahoma University Health Sciences Center

Simon Moore

Global Lead of Inhalation Sciences and Engineering at Labcorp

Simone Carneiro

Postdoctoral Fellow at LMU Munich



Marian Asch

Senior Sales Manager at Harro Höfliger

Ulf Krueger

Chief Executive Officer at PULMOTREE

Stephen F. Flaim

Senior Special Advisor & Investor-In-Residence at National Heart Lung and Blood Institute, NIH

Ronan MacLoughlin

Director of R&D, Science and Emerging Technologies at Aerogen Limited

Carla Vozone

VP Inhalation Strategy, Innovation and Partnerships at Catalent Pharma Solutions

Stephen Pham

Senior Vice President, Product Development of Avalyn Pharma, Inc.

Volker Dickfeld

Sr. Marketing Manager Healthcare Global at Avient

Marcus Jarman-Smith

Head of Marketing in Medical at Victrex

Andreas Meliniotis

VP of Device Development at Vectura

Scientific **Agenda**

DAY 0 JUN 26.2024

18:00 - 20:00 Pre-Conference Cocktail Reception GOJA ROOFTOP at Renaissance Barcelona Hotel

DAY 1 JUN 27.2024

08:00 – 08:20 RESCON Summit Registration

Session 1
Exploring Future Trends in Drug Delivery

Morning Chairperson:
Marian Asch, Harro Höfliger

08:30 – 09:00 PEEK polymers: a case study in soft mist inhaler innovation through material selection
Dr Marcus Jarman-Smith
Head of Marketing - Medical at Victrex

09:00 – 09:30 Drug delivery strategy developing high doses and/or biologics to the lung
Gunilla Petersson
Strategic Scientific Advisor at HCmed Innovations Co., Ltd.

09:30 – 10:00 Respimat Soft Mist Inhaler – comparison with nebulizers
Felix Weiland
Head of Device Technology at Boehringer Ingelheim
Respimat Soft Mist Inhaler – comparison with nebulizers

10:00 – 10:30 Speed Networking

10:30 – 11:00 Morning Coffee-Break

10:40 Harro Höfliger Sponsor Presentation (5min)

10:50 Vectura Sponsor Presentation (5min)

Session 2
Advances in Inhalation Formulations

11:00 – 11:30 X-Ray as process analytical technology and its contribution to DPI blister development
Marian Asch
Senior Sales Manager at Harro Höfliger

11:30 – 12:00 Dry powder aerosols using nanocrystals to maximize Dry powder aerosols using nanocrystals to maximize dose and enhance stability of inhaled formulations

Lucila Garcia-Contreras
Associate Professor at Oklahoma University Health Sciences Center

Session 3
Sustainable Development and Environmental Impact

12:00 – 12:30 How a material supplier can help you achieve your sustainability goals for medical devices

Volker Dickfeld
Sr. Marketing Manager Healthcare Global at Avient

12:30 – 13:00 The Innovation Imperative: Regulatory & Design; Design Strategies for a Sustainable Competitive Advantage in Respiratory Devices

Jacqueline van Druten
Clinical & Regulatory Affairs Director at CLIN-r+

13:00 – 14:00 Lunch Break

Session 4
Regulatory Compliance, Safety, and Pre-Clinical Assessment

Afternoon Chairperson:
Loy Britto, Healthy Airways LLC

14:00 – 14:30 Evolution of Metered Dose Inhaler Formulations: Navigating Technical and Regulatory Hurdles in Transitioning from High GWP to Low GWP Propellants with a Focus on Ambitious Climate and Patient Benefit Timelines

Loy Britto
Chief Executive Officer at Healthy Airways LLC

14:30 – 15:00 General pre-clinical overview

Simon Moore
Global Lead of Inhalation Sciences and Engineering at Labcorp

15:00 – 15:30 "The ever changing expectations from authorities on biological safety evaluations of breathing gas pathway devices"

Lina Burman
Senior Scientific Affairs Manager at Veranex

15:30 – 16:00 Regulatory Perspectives for Device Development for Inhalation Combination Products

Deepika Lakhani
Senior Vice President, Chief Regulatory & Quality Officer at PAVmed Inc.

16:00 – 16:30 Afternoon Coffee-Break

16:10 Berry Global Sponsor Presentation (5min)

16:30 – 17:30 **Panel discussion: Charting the Future of Inhalation Therapies: Innovations, Regulations, and Market Trends**

• Innovations in Drug Delivery
• Collaboration and Simplification to Accelerate Device Development and Drug Delivery
• Market Dynamics and Investment Opportunities
• Regulatory Strategy for Combination Devices: Working with the FDA for Program Success

Panelists:

• Gunilla Petersson, HCmed Innovations
• Deepika Lakhani, PAVmed Inc
• Stephen F. Flaim, National Heart Lung and Blood Institute, NIH
• Loy Britto, Healthy Airways LLC
• Felix Weiland, Boehringer Ingelheim
• Jacqueline van Druten, CLIN-r+

moderated by Carla Vozone, Catalent Pharma Solutions

17:30 Closing remarks & End of first day sessions

20:00 – 22:00 RESCON Europe & INJECTA Summit Gala Dinner CRU Restaurant at Renaissance Barcelona Hotel

DAY 2 JUN 28.2024

08:50 - 09:00 Opening of the RESCON Europe 2nd day

Session 5
Advancements in Therapeutics

Morning Chairperson:
Ronan MacLoughlin, Aerogen Limited

09:00 – 09:30 Enabling next generation therapeutics and prophylactics – inhaled gene therapies and vaccines

Ronan MacLoughlin
Director of R&D, Science and Emerging Technologies at Aerogen Limited

09:30 – 10:00 Inhaled alkaline HDS for treatment of refractory chronic cough

David Edwards
Associate Professor at Harvard University & Advisory Board at Johns Hopkins Medical School

10:00 – 10:30 Polysaccharide-based inhalable dry powders: enabling tools in lung drug delivery

Ana Grenha
Associate Professor at University of Algarve

10:30 – 11:00 Morning Coffee-Break

10:40 Credence MedSystems, Inc. Sponsor Presentation (5min)

11:00 – 11:30 The evolution of a family of multi-dose DPIs

Andreas Meliniotis
VP of Device Development at Vectura

Session 6
Future Trends in Inhalation Therapy

11:30 – 12:00 Detoxing and Empowering: If not now, then when? Some thoughts on Industry 4.0 inhalation devices and their impact on patient, environment and the medical field

Marco Franza
Director Sales and Business Development at Global Inhalation & Medical Devices – Berry Healthcare

12:00 – 12:30 Mitigating N-Nitrosamine Risks with Novel Active Material Science Innovations

Badre Hammond
VP Global Commercial Operations & GM APAC at Aptar CSP Technologies

---

Session 7
Connectivity and Remote Monitoring

12:30 – 13:00 Connectivity and remote monitoring in nebulized therapies: a look into the future?

Ulf Krueger
CEO and Founder at Pulmotree Medical

13:00 – 14:00 Lunch Break

Session 8
Cutting-edge Research in Respiratory Medicine

Afternoon Chairperson:
Nathalie Wauthoz, Université libre de Bruxelles

14:00 – 14:30 Inhaled chemotherapy as a new modality to increase immunotherapy response in lung cancer therapy

Nathalie Wauthoz
Associate Professor at Université libre de Bruxelles

14:30 – 15:00 CRISPR/Cas9-LNPs for gene editing in lung cancer cells

Simone Carneiro
Postdoctoral Fellow at LMU Munich

15:00 – 15:30 Development of Inhaled Pirfenidone for Treatment of Pulmonary Fibrosis

Stephen Pham
Senior Vice President, Product Development of Avalyn Pharma, Inc.

15:30 Closing Remarks and End of RESCON Europe 2024

DOSE BETTER

The RS01X inhaler offers **better adherence** for patients needing administration management for pulmonary disease drugs. Berry Global has partnered with Amiko Digital Health to accurately capture patient inhalation parameters through their Respiro sensors and Bluetooth technology, significantly improving therapy adherence and inhalation technique overtime*. With investments in the latest patient-centric designs, Berry commits to provide solutions that **dose better**.

INNOVATION FOR THE WORLD

Berry

SOLUTIONS FOR YOU

Connect with a Berry Inhalation Expert at RESCON

*Gonzalez et al. (2024). *Unlocking the Promise of Digital Inhalers: Insights From an in Vitro Study.* solvias.

Biographies

Ana Grenha Associate Professor at Drug Delivery Lab, University of Algarve

Ana Grenha has received her PhD in Pharmacy-Pharmaceutical Technology from the University of Santiago de Compostela – Spain in 2007. She joined the University of Algarve in Portugal for a Professorship in Pharmaceutical Technology in 2007 and received her Habilitation in Pharmaceutical Technology at the University of Lisbon in 2022. Since July 2023 she is Associate Professor in Pharmaceutical Technology. She is a Senior Researcher at the Centre for Marine Sciences (CCMAR-UAlg) and an active collaborator of the iMed from the Faculty of Pharmacy of the University of Lisbon, being the PI of the Drug Delivery Laboratory, which is mainly dedicated to respiratory drug delivery, with a particular focus on inhalation. The research group is also keen on exploring the potential of natural materials, namely polysaccharides, fostering new applications that benefit from their intrinsic properties.

Badre Hammond VP Global Commercial Operations & GM APAC at Aptar CSP Technologies

Badre Hammond's background is in biochemistry and drug development with 18 years' experience in pharmaceutical product development, packaging, and drug delivery systems. Badre has broad experience in managing development of novel drug product programs from formulation development, through pre-clinical and CMC, all the way to market launch. As the VP of Global Commercial Operations and General Manager APAC for Aptar CSP Technologies, his current focus is on commercial best practices, strategy, and business development globally, as well as expanding commercial synergies and bringing Aptar CSP's active material science platform technology to the APAC region.

Felix Weiland Head of Device Technology at Boehringer Ingelheim microParts GmbH

Felix is a pharmacist by training with a PhD in pharmacology. In 2006, he joined Boehringer Ingelheim as a trainee, focusing on launch and transfer activities of inhalative products. He took over different roles at BI microParts for development of inhalation devices as QA Head, senior project manager and lab head for design engineering. In 2010, he joined the Ger-resheimer Group as a QC head and later on quality director for large-scale manufacturing of sterile primary packaging components, i.e.RTF®- syringes and insulin cartridges. In 2015, he returned to Boehringer Ingelheim to implement structures for life cycle management of the Respimat® Plat¬form Technology, including ownership of design history files for existing products and launching the new Respimat Reusable® in Europe in 2018. Currently he is the director of Device Technology in operations.

David Edwards Associate Professor at Harvard University & Advisory Board at Johns Hopkins Medical School

David Edwards is a scientist, inventor and writer. The founder and inventor of FEND, 2020 Time Magazine Best Invention of the Year, a new daily rite for cleansing the lungs, David's inventions and startups have led to FDA-approved products on the market such as Inbrijia (inhaled L Dopa for Parkinson's). David was Professor of the Practice of Bioengineering at Harvard University in the School of Engineering & Applied Sciences from 2001 to 2019, and transitioned to Associate at the start of the pandemic to help pioneer the science and global clinical trial program of airway hydration.

Simon Moore Global Lead of Inhalation Sciences and Engineering at Labcorp

Simon joined the company in 1999 as an inhalation study analyst and was promoted quickly within the Aerosol Technology and Analysis section. When the section expanded and divided in 2003 into inhalation chemistry and aerosol technology, Simon was promoted to the role of Head of Aerosol Technology with managerial responsibility for the aerosol In 2009, he took managerial responsibility for the inhalation engineering services group. The inhalation engineering services groups designs, prototypes and manufactures custom made inhalation equipment for all sites within the organisation. In July 2017, Simon took on the additional responsibility of being part of the Toxicology Operations Management as a Team Leader of the inhalation study management team with line management responsibility for Study Managers and Trainee Study Managers in the Inhalation Studies Group.

Simone Carneiro Postdoctoral Fellow at LMU Munich

Dr. Simone Carneiro holds a Pharmacy degree and completed her Ph.D. in Biotechnology at the Federal University of Ouro Preto (UFOP), Brazil, in 2019. During her doctoral studies, she embarked on a year of international mobility at Université Paris-Sud, France, further enriching her research on the development of inhaled nanoparticles for tuberculosis treatment. Currently, she serves as a Postdoc at the Ludwig-Maximilians-University of Munich, Germany. She is funded by the Georg Forster Research Fellowship, a prestigious grant awarded by the Alexander von Humboldt Foundation. Her research is primarily centered on the development of RNA-based lipid nanoparticles for pulmonary delivery. She has experience with formulation characterization, optimization, and in vitro assessment, including several techniques.

Marian Asch Senior Sales Manager at Harro Höfliger

Marian Asch has a BSc. degree in business and engineering from University of Stuttgart. He started his career as Project Manager in Harro Hoefligers Business Unit Inhalation in 2017. In this role he managed DPI projects of multinational pharma clients worldwide. Since summer 2021, Marian Asch works as a Sales Manager for Inhalation Technologies focusing on business development and sales for dry powder inhaler pharma industry.

Ulf Krueger Chief Executive Officer at PULMOTREE

Ulf Krueger´s deep knowledge in respiratory drug delivery combined with his strong management skills and innovative entrepreneurial vision are the foundation of PULMOTREE. His comprehensive experience involves key areas across the non-propellant liquid inhaler lifecycle, from research and development, through corporate strategy to successful commercialization. In his former position as Director – Fox Nebuliser Programs at Vectura, he was responsible for the entire sector of the proprietary mesh nebulizers business. Previously, he held various positions in the research and development department at PARI. He is a graduate biomedical engineer, an inventor listed on numerous patents, and recognized speaker and conference chairman. As a member of The Aerosol Society, and the European Respiratory Society (ERS), he is particularly also involved as PhD student mentor for the TANDEM program at RWTH Aachen University, and chairman of the networking group New Devices, Emerging Therapies and e-Health at the InternationalSociety for Aerosols in Medicine (ISAM).

Gunilla Petersson Strategic Scientific Advisor at HCmed Innovations Co., Ltd.

As former Science and Innovation Director of Inhaled Drug Delivery at AstraZeneca, Dr. Petersson has 30 years of experience in the pharmaceutical industry. Affiliated to the Innovation Strategies and External Liaison segment, in most recent years, she dedicated herself to novel technology development and scouting, due diligence activities, feasibility studies and scientific marketing. During her extended and successful professional career, Dr. Petersson has also focused on development of inhaled medicines, medical devices (inhalers), pharmaceutical research, quality by design, and regulatory documentation, accumulating a vast number of connections with global pharmaceutical companies and renowned experts in the field. Today acting Strategic Scientific Advisor for HCmed, Board member in Medicon Valley Inhalation Consortium (MVIC) as well as independent consultant in the field and inhaled drug delivery.

Lina Burman Senior Scientific Affairs Manager at Veranex

Lina Burman is a chemist by training with a PhD in polymer technology, focusing on the evaluation of migration and degradation behavior of polymeric materials. She has over 15 years of experience in the medical device industry, mainly working with biocompatibility evaluations and toxicological risk assessments. She was responsible for the biocompatibility evaluations of the ventilator and anesthesia portfolio of Getinge for 10 years and got involved during these years in the initiation and writing of ISO 18562. She has thereafter continued to be active in the work with the standard series as nominated expert. The last seven years Lina Burman has worked as consultant with evaluation of a broad range of devices, class I – III for mainly the EU and US markets. Above ISO 18562, she is also active in work with some of the ISO 10993 standard parts.

Loy Britto Chief Executive Officer at Healthy Airways LLC

Loy Britto presently serves as the CEO of Healthy Airways LLC, where he offers consultancy services to the pharmaceutical industry, specializing in the development, registration, and commercialization of Orally Inhaled and Nasal Drug Products (OINDP). With profound technical, scientific, and practical expertise, Loy advises clients ranging from pharmaceutical companies, device component manufacturers to suppliers of excipients for inhaled products. Additionally, he holds the position of Chief Scientific Officer at Sonohaler. Prior to his role at Healthy Airways LLC, Loy worked for over three decades at GlaxoSmithKline (GSK). Throughout his tenure at GSK, he contributed extensively to the development and commercialization of inhaled products, spanning various delivery platforms such as metered dose inhalers (MDIs), dry powder inhalers (DPIs), and smart mist inhalers (SMIs).

Nathalie Wauthoz Associate Professor at Université libre de Bruxelles

Nathalie Wauthoz obtained her PharmD degree in 2006 at Université libre de Bruxelles (ULB). She obtained her PhD degree in Biomedical and Pharmaceutical sciences in 2011 under the supervision of Prof. K. Amighi in Laboratory of Pharmaceutics and Biopharmaceutics (LPB) at ULB. She performed several post-doctoral positions and one of them in the Prof. J.P. Benoit's Mint unit, INSERM UMR-S 1066 (Angers, France). Since 2017, she is Associate Professor in LPB where she manages and develops the research projects in inhalation field. She had supervised/is supervising 10 PhD students until now. She has published more than 50 peer-reviewed papers in internationally recognized journals, more than 50 abstracts and conference proceedings and is co-inventor on 5 patents. She is also co-founder of the InhaTarget Therapeutics, a spin-off company of the ULB dedicated to the development of innovative dry powders for inhalation (DPIs).

Stephen Pham Senior Vice President, Product Development of Avalyn Pharma, Inc.

Stephen Pham, Ph.D., is Senior Vice President, Product Development of Avalyn Pharma, Inc. Dr. Pham has over 25 years of industry experience in inhalation and ophthalmic products. Prior to joining Avalyn, Dr. Pham served as a full-time consultant for Sunovion Pharmaceuticals where from Phase 2 through NDA submission and review, Dr. Pham was responsible for Lonhala® Magnair® product development (glycopyrrolate inhalation solution for maintenance treatment of COPD). Prior to Sunovion, he was Senior Director at Elevation Pharmaceuticals where he was responsible for Lonhala Magnair CMC until the Sunovion acquisition in 2012. Previously at Dey Laboratories (now Mylan), Dr. Pham was an inventor of Perforomist® (formoterol fumarate inhalation solution for maintenance treatment of COPD) and responsible for its development and approval. Dr. Pham was also an inventor of Bromsite® (bromfenac ophthalmic solution for post-operative ocular inflammation and pain).

Stephen F. Flaim Senior Special Advisor & Investor-In-Residence at National Heart Lung and Blood Institute, NIH

Dr. Flaim holds a doctorate in Human Physiology and Pharmacology from the University of California at Davis. He held faculty positions in Medicine & Physiology at the Pennsylvania State University College of Medicine and senior management roles at the Johnson & Johnson Pharmaceutical Research Institute, the Squibb Institute for Medical Research, Alliance Pharmaceutical Corporation, Trega Biosciences, Inc., Galileo Pharmaceuticals, Inc., OncoFluor, Inc., CardioCreate, Inc. and Leading Biosciences, Inc. Dr. Flaim is a Fellow of the American College of Cardiology, the American Heart Association, the American College of Clinical Pharmacology & the Royal Society of Medicine. Dr. Flaim is Chair Emeritus of the Board of Governors for the Tech Coast Angels, Past President & Chair Emeritus of the San Diego Network of Tech Coast Angels & Emeritus Director of the Angel Capital Association. He is a member of the Editorial Board of the Journal of Pharmacology & Experimental Therapeutics, founding member of the Board of Directors & CEO for the John G. Watson Foundation, Inc. & is active in numerous regional & national scientific organizations.

Ronan MacLoughlin Director of R&D, Science and Emerging Technologies at Aerogen Limited

Dr Ronan MacLoughlin, PhD, MBS is currently Director of R&D, Science and Emerging Technologies in Aerogen Limited. Dr MacLoughlin has more than 20 years' experience in Respiratory Drug Delivery with several nebuliser, and accessory product launches over that time. He has responsibility for new product development, establishing and exploiting the science underpinning respiratory drug delivery and identifying new and potentially disruptive emerging technologies. To this end, he has developed multiple technologies and products with several patents granted and pending, that cover the range of drug, device, drug/device combination products, patient interventions, and patient interfaces. Of note, this includes the world's first fit for purpose mass vaccination by inhalation delivery system, currently in use with Convidicia Air, the first approved inhaled COVID-19 vaccine. Dr MacLoughlin was also previously head of Medical Affairs in Aerogen.

Carla Vozone VP Inhalation Strategy, Innovation and Partnerships at Catalent Pharma Solutions

Carla Vozone is Vice President of Inhalation Strategy, Innovation and Partnerships at Catalent Pharma Solutions. Carla leads strategic growth initiatives for Catalent's Inhalation business segment and oversees Product Development for Nasals and Inhaled Powders. She holds a PharmD and MSc in Pharmaceutical Technology from the Pharmacy School, University of Lisbon, a Master in Business Administration (MBA) with a specialization in Pharmaceutical Management from Rutgers Business School, New Jersey and a Certification in Business Development and Licensing from the University of Manchester. Carla is Immediate Past Chair of IPAC-RS, the leading industry consortium on regulatory science of orally inhaled and nasal drugs (OINDPs).

Marco Franza Director Sales and Business Development at Global Inhalation & Medical Devices – Berry Healthcare

Marco covered different roles in Sales, Business Development and Marketing. As Inhalation devices have constantly been identified as the key growth factor for the company, Marco always had a particular focus on them, driven also by personal interest. 1997 to 2019: Sales, Marketing and Key Accounts Director at Plastiape Since 2020: Director Sales and Business Development – Global Inhalation & Medical Devices – Berry Healthcare

Deepika Lakhani Senior Vice President, Chief Regulatory & Quality Officer at PAVmed Inc.

Dr. Deepika Lakhani is an internationally recognized regulatory professional with over 15 years of experience with the Food and Drug Administration (FDA) and industry. Her interest in regulatory affairs started during her Doctorate studies at Virginia Commonwealth University where she collaborated with the FDA on an academic research project that fostered her interest in understanding regulations impacting the pharmaceutical and medical device industry. Right out of graduate school she started working as a reviewer at the Center for Drugs Evaluation and Research at the FDA where she spent >5 years in different capacities followed by >5 years at Center for Devices and Radiological Health. During her tenure at the FDA, she has reviewed, led cross-discipline teams, and contributed to policies impacting drugs, biologics, medical devices, tobacco products and combination products and served as FDA's liaison to ISO committees.

Jacqueline van Druten Clinical & Regulatory Affairs Director at CLIN-r+

Jacqueline van Druten (MICR.CIM.RD) is a healthcare professional with extensive experience in Clinical Regulatory Affairs. With a passion for MedTech, Jacqueline has been a driving force building CLIN-r+ EU MDR submissions automation and fast track Clinical Development Strategy workflow for EU MDR submissions for Med Tech manufacturers. Her expertise is backed by 20 years of hands-on experience in healthcare research and medical innovations. As a contributor and lead in Research, Regulatory and Clinical Affairs at various multi-national medical organisations, Jacqueline has been instrumental in supporting the translation of medical interventions into measurable patient outcome data. Enabling healthcare innovations obtain regulatory clearance, market access and product differentiation to meet their investment promise.

Lucila Garcia-Contreras Associate Professor at The University of Oklahoma Health Sciences CenterSolutions

Dr. Lucila Garcia-Contreras is Associate Professor in the Department of Pharmaceutical Sciences at the Oklahoma University Health Sciences Center. She obtained her Ph.D. degree in Pharmaceutical Sciences from The University of Georgia, with a Fulbright Scholarship. Following a postdoctoral position at the University of North Carolina at Chapel Hill Eshelman School of Pharmacy, Dr. Garcia-Contreras moved up the ranks to Research Associate Professor. During these years, she focused on the design, formulation and evaluation of drugs and vaccines delivered by the pulmonary route for the treatment and prevention of tuberculosis. In 2011 Dr Garcia-Contreras joined the faculty of the College of Pharmacy at the University of Oklahoma Health Sciences Center where she has extended her research to other respiratory infectious diseases and to novel approaches to treat gynecological and lung cancers.

Andreas Meliniotis VP of Device Development at Vectura

Andreas Meliniotis is VP of Device Development at Vectura and leads the engineering and device development group based in Cambridge, UK. With over 20 years' experience at Vectura, he has led the design and development of several multidose dry powder inhalers as well as nebulisers and connected device technology. Prior to joining Vectura, Mr Meliniotis worked for Cambridge Design Partnership and The Technology Partnership, developing glucose measurement devices and industrial printing technology, respectively. He is a Chartered Mechanical Engineer and Chartered Manager and holds a bachelor's degree in mechanical engineering from the University of Nottingham (UK).

Volker Dickfeld Sr. Marketing Manager HealthCare Global at Avient Colorants Germany GmbH

35 Year in the company. Various Sales, and Marketing Positions. Over 12 years abroad in Italy, France, China, and New Zealand. In the last 3-year Marketing responsible for Avient´s Mevopur Healthcare solutions. And always passioned about supporting customers to find solutions for their challenges in the plastics industry.

Marcus Jarman-Smith Head of Marketing in Medical at Victrex

Dr Marcus Jarman-Smith is Head of Marketing in Medical at Victrex, working with PEEK-based materials and technology platforms to help solve complex design and engineering challenges. He has been working with PEEK, a high-performance polymer, since 2006 in various technical and commercial roles across industrial and medical markets. Dr Jarman-Smith's specialist areas are medical implants, and pharmaceutical drug delivery applications.


R

Renaissance Barcelona Hotel



Discover the vibrant spirit of Barcelona's Eixample neighborhood at Renaissance Barcelona Hotel. With 211 stylish guest rooms and suites, this 5-star downtown retreat offers unique contemporary design and destination-focused flair. Engage with a dynamic community that transforms day and night, indulge in authentic flavors and chilled vibes at Rumbo Bar & Eatery, or savor crafted cocktails and Mediterranean cuisine with captivating views at Goja Rooftop. Whether you choose to stay active in the gym or unwind at the Mayan Luxury Spa cabin, the hotel provides limitless relaxation. For the inventive creatives, there's ample space to meet and collaborate. Onsite parking is available for convenience. Connect with the Navigator to discover the latest and greatest in the area, and within walking distance of iconic landmarks, this luxury hotel is the ideal choice for those seeking an extraordinary experience from a prime location.

Renaissance Barcelona Hotel
C/ de Pau Claris, 122, L'Eixample,
08009 Barcelona, Espanha





rescon-europe.com